Sensus Healthcare Installs Second Next-Generation SRT-100 Vision System in Israel to Treat Skin Cancer and Keloids
New SRT-100 Vision Now at Beilinson Hospital / Rabin Media Center in Petah Tikva
BOCA RATON, Fla. – September 20, 2017 – Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancer and other skin conditions, such as keloids, with superficial radiotherapy (SRT), today announced that the Company has recently installed its second SRT-100 Vision™ system in Israel, with the newest unit located at the Beilinson Hospital / Rabin Medical Center in Petah Tikva. The first unit was previously installed at the Ichilov Hospital in Tel Aviv in 2016.
“SRT is a game-changer when it comes to treating both non-melanoma skin cancer and symptomatic keloids – without the need for invasive, costly and painful surgery – and this latest installation in Israel highlights Sensus’ dedication to bringing this highly effective treatment to patients in need all over the world,” said Joe Sardano, Sensus Healthcare CEO. “As we continue to expand our global footprint, this latest installation marks an important next step toward revolutionizing non-melanoma skin cancer and keloid treatment as we know it today.”
The SRT-100 Vision features a unique integration of multi-modal therapy and image-guidance technologies with software integration to provide enhanced precision, safety and quality in delivering SRT, electronic brachytherapy (eBx) and Grenz Ray therapy (GRT) in a seamlessly integrated and scalable platform. The device allows for basal and squamous cell carcinomas, as well as keloid tissue, to be assessed more thoroughly, and treatment is more precisely targeted. The SRT-100 Vision also allows physicians to better examine how the lesion is progressing with each treatment session and records each session for the patient’s records via the LesionCam™.
The SRT-100 Vision received FDA clearance for the treatment of non-melanoma skin cancer and keloids in 2015.
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiotherapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://www.sensushealthcare.com.
The Benefits of SRT
Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:
- 95%+ cure rates that rival surgery
- No anesthesia, cutting, bleeding, stitching or pain
- No downtime or lifestyle restrictions
- Super cosmesis, no unsightly scarring
- No need for post-treatment reconstructive surgeries